News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Probiodrug AG Presents Pre-clinical And Clinical Findings Of PQ912, A QC-Inhibitor For Alzheimer's Disease



7/31/2014 11:47:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HALLE/SAALE, Germany--(BUSINESS WIRE)--Probiodrug AG (Probiodrug) announced today that Dr. Stephan Schilling, an expert consultant to the Company, will give an invited presentation at the upcoming Gordon Research Conference: Medicinal Chemistry, The Leading Edge of Drug Discovery. Dr. Schilling was head of enzymology at Probiodrug until 2013, during which he was crucial to the discovery of the function of glutaminyl cyclase (QC) in modifying brain Abeta from its normal state to the toxic pyroglutamated (pGlu)-Abeta. Dr. Schilling’s work provided the basis for Probiodrug’s development of QC-inhibitors as a novel treatment approach for Alzheimer’s disease (AD). Dr. Schilling is author and co-author of more than 45 peer-reviewed papers on QC and other topics. The Gordon Research Conference presentation is titled “Discovery and Development of Glutaminyl Cyclase Inhibitors: A New Approach for the Treatment of AD.” It takes place on Tuesday, August 5 in New London, New Hampshire, USA. In his presentation, Dr. Schilling will summarize pre-clinical and clinical findings from Probiodrug’s studies of PQ912, the Company’s lead QC inhibitor.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES